The impact of intestinal resection on serum levels of anti-Saccharomyces cerevisiae antibodies (ASCA) in patients with Crohn's disease

Alimentary Pharmacology and Therapeutics

Volumn 35, Issue 2, 2012, Pages 292-299

  Eser, A ^a   Papay, P ^a   Primas, C ^a   Pernicka, E ^a   Harrer, M ^a   Dejaco, C ^a   Novacek, G ^a   Lichtenberger, C ^a   Angelberger, S ^a   Kazemi, L ^a   Mikulits, A ^a   Vogelsang, H ^a   Reinisch, W ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; FUNGUS ANTIBODY; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; INFLIXIMAB; MESALAZINE; PREDNISOLONE; SACCHAROMYCES CEREVISIAE ANTIBODY; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ANTIBODY PRODUCTION; ANTIBODY TITER; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; CROHN DISEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; FOLLOW UP; HEMICOLECTOMY; HUMAN; IMMUNE RESPONSE; INTESTINE OBSTRUCTION; INTESTINE RESECTION; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; POSTOPERATIVE PERIOD; PREDICTIVE VALUE; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROSPECTIVE STUDY; REOPERATION; RISK ASSESSMENT; SMALL INTESTINE RESECTION;

ADULT; AGED; ANASTOMOSIS, SURGICAL; ANTIBODIES, BACTERIAL; CROHN DISEASE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; POSTOPERATIVE PERIOD; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; SACCHAROMYCES CEREVISIAE; TIME FACTORS; YOUNG ADULT;

EID: 83855165082     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2011.04932.x     Document Type: Article

References (29)

1. Sartor RB,. Mechanisms of disease: pathogenesis of Crohn's disease and ulcerative colitis. Nat Clin Pract Gastroenterol Hepatol 2006; 3: 390-407. (Pubitemid 44018812)
2. Sachar DB,. The problem of postoperative recurrence of Crohn's disease. Med Clin North Am 1990; 74: 183-8.
3. Thayer WR Jr,. Inflammatory bowel disease: where are the frontiers? Med Clin North Am 1980; 64: 1221-31. (Pubitemid 11184728)
4. Olaison G, Smedh K, Sjodahl R,. Natural course of Crohn's disease after ileocolic resection: endoscopically visualised ileal ulcers preceding symptoms. Gut 1992; 33: 331-5.
5. McLeod RS, Wolff BG, Steinhart AH, et al. Risk and significance of endoscopic/radiological evidence of recurrent Crohn's disease. Gastroenterology 1997; 113: 1823-7. (Pubitemid 27512140)
6. Rutgeerts P, Geboes K, Vantrappen G, Beyls J, Kerremans R, Hiele M,. Predictability of the postoperative course of Crohn's disease. Gastroenterology 1990; 99: 956-63. (Pubitemid 20338451)
7. Bossuyt X,. Serologic markers in inflammatory bowel disease. Clin Chem 2006; 52: 171-81. (Pubitemid 43185477)
8. Schoepfer AM, Schaffer T, Mueller S, et al. Phenotypic associations of Crohn's disease with antibodies to flagellins A4-Fla2 and Fla-X, ASCA, p-ANCA, PAB, and NOD2 mutations in a Swiss Cohort. Inflamm Bowel Dis 2009; 15: 1358-67.
9. Russell RK, Ip B, Aldhous MC, et al. Anti-Saccharomyces cerevisiae antibodies status is associated with oral involvement and disease severity in Crohn disease. J Pediatr Gastroenterol Nutr 2009; 48: 161-7.
10. Walker LJ, Aldhous MC, Drummond HE, et al. Anti-Saccharomyces cerevisiae antibodies (ASCA) in Crohn's disease are associated with disease severity but not NOD2/CARD15 mutations. Clin Exp Immunol 2004; 135: 490-6. (Pubitemid 38297152)
11. Dassopoulos T, Frangakis C, Cruz-Correa M, et al. Antibodies to Saccharomyces cerevisiae in Crohn's disease: higher titers are associated with a greater frequency of mutant NOD2/CARD15 alleles and with a higher probability of complicated disease. Inflamm Bowel Dis 2007; 13: 143-51. (Pubitemid 46806222)
12. Odes S, Friger M, Vardi H, et al. Role of ASCA and the NOD2/CARD15 mutation Gly908Arg in predicting increased surgical costs in Crohn's disease patients: a project of the European Collaborative Study Group on Inflammatory Bowel Disease. Inflamm Bowel Dis 2007; 13: 874-81. (Pubitemid 47203865)
13. Vermeire S, van Assche G, Rutgeerts P,. Review article: altering the natural history of Crohn's disease-evidence for and against current therapies. Aliment Pharmacol Ther 2007; 25: 3-12. (Pubitemid 44902859)
14. Main J, McKenzie H, Yeaman GR, et al. Antibody to Saccharomyces cerevisiae (bakers' yeast) in Crohn's disease. BMJ 1988; 297: 1105-6.
15. Satsangi J, Silverberg MS, Vermeire S, Colombel JF,. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut 2006; 55: 749-53. (Pubitemid 43764536)
16. Teml A, Kratzer V, Schneider B, et al. Anti-Saccharomyces cerevisiae antibodies: a stable marker for Crohn's disease during steroid and 5-aminosalicylic acid treatment. Am J Gastroenterol 2003; 98: 2226-31. (Pubitemid 37305363)
17. Ruemmele FM, Targan SR, Levy G, Dubinsky M, Braun J, Seidman EG,. Diagnostic accuracy of serological assays in pediatric inflammatory bowel disease. Gastroenterology 1998; 115: 822-9. (Pubitemid 28452928)
18. Israeli E, Grotto I, Gilburd B, et al. Anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic antibodies as predictors of inflammatory bowel disease. Gut 2005; 54: 1232-6. (Pubitemid 41192480)
19. Landers CJ, Cohavy O, Misra R, et al. Selected loss of tolerance evidenced by Crohn's disease-associated immune responses to auto- and microbial antigens. Gastroenterology 2002; 123: 689-99. (Pubitemid 34977074)
20. Muller S, Styner M, Seibold-Schmid B, et al. Anti-Saccharomyces cerevisiae antibody titers are stable over time in Crohn's patients and are not inducible in murine models of colitis. World J Gastroenterol 2005; 11: 6988-94. (Pubitemid 43126058)
21. Vermeire S, Peeters M, Vlietinck R, et al. Anti-Saccharomyces cerevisiae antibodies (ASCA), phenotypes of IBD, and intestinal permeability: a study in IBD families. Inflamm Bowel Dis 2001; 7: 8-15.
22. Papp M, Foldi I, Altorjay I, et al. Anti-microbial antibodies in celiac disease: trick or treat? World J Gastroenterol 2009; 15: 3891-900.
23. Granito A, Zauli D, Muratori P, et al. Anti-Saccharomyces cerevisiae and perinuclear anti-neutrophil cytoplasmic antibodies in coeliac disease before and after gluten-free diet. Aliment Pharmacol Ther 2005; 21: 881-7. (Pubitemid 40477248)
24. Forcione DG, Rosen MJ, Kisiel JB, Sands BE,. Anti-Saccharomyces cerevisiae antibody (ASCA) positivity is associated with increased risk for early surgery in Crohn's disease. Gut 2004; 53: 1117-22. (Pubitemid 38961964)
25. Amre DK, Lu SE, Costea F, Seidman EG,. Utility of serological markers in predicting the early occurrence of complications and surgery in pediatric Crohn's disease patients. Am J Gastroenterol 2006; 101: 645-52. (Pubitemid 43340944)
26. Desir B, Amre DK, Lu SE, et al. Utility of serum antibodies in determining clinical course in pediatric Crohn's disease. Clin Gastroenterol Hepatol 2004; 2: 139-46. (Pubitemid 38180468)
27. Avidan B, Sakhnini E, Lahat A, et al. Risk factors regarding the need for a second operation in patients with Crohn's disease. Digestion 2005; 72: 248-53. (Pubitemid 41820810)
28. Cosnes J, Carbonnel F, Beaugerie L, Le Quintrec Y, Gendre JP,. Effects of cigarette smoking on the long-term course of Crohn's disease. Gastroenterology 1996; 110: 424-31. (Pubitemid 26043875)
29. Bourreille A, Jarry M, D'Halluin PN, et al. Wireless capsule endoscopy versus ileocolonoscopy for the diagnosis of postoperative recurrence of Crohn's disease: a prospective study. Gut 2006; 55: 978-83.